ProDGNE is a collaborative effort combining patient experience, complementary, and synergist expertise in glycobiology, biochemistry, medicinal chemistry, clinical pharmacology, -omics, biomarker discovery, pharmaceutical technology and clinical expertise to develop proof of principle of novel attractive compounds to treat GNE Myopathy (GNEM) and bring lead compounds one step closer to patients.
ProDGNE is a collaborative effort combining patient experience, complementary, and synergist expertise in glycobiology, biochemistry, medicinal chemistry, clinical pharmacology, -omics, biomarker discovery, pharmaceutical technology and clinical expertise to develop proof of principle of novel attractive compounds to treat GNE Myopathy (GNEM) and bring lead compounds one step closer to patients.
ABOUT
What is ProDGNE?
ProDGNE is a 3 year transnational pre-clinical research project which aims to develop an innovative therapeutic compound to treat GNEM, an ultra rare muscle disease affecting young adults.
ProDGNE representes a unique joint collaboration among patients, European and Canadian experts in clinical GNEM, sialic acid, organic synthesis, and -OMIC Technologies.
News
29May
18Mar
ProDGNE Meeting 2024: An international Meeting
ProDGNE International Meeting on GNE Myopathy 2024 Cagliari, 19-20 April 2024
